These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. Starr SE; Glazer JP; Friedman HM; Farquhar JD; Plotkin SA J Infect Dis; 1981 Apr; 143(4):585-9. PubMed ID: 6263984 [TBL] [Abstract][Full Text] [Related]
9. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Gonczol E; Plotkin S Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Adler SP; Hempfling SH; Starr SE; Plotkin SA; Riddell S Pediatr Infect Dis J; 1998 Mar; 17(3):200-6. PubMed ID: 9535246 [TBL] [Abstract][Full Text] [Related]
11. [The prevention of cytomegalovirus infection and disease by administration of biological products]. Ihara T Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680 [TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181 [TBL] [Abstract][Full Text] [Related]
13. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299 [TBL] [Abstract][Full Text] [Related]
14. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679 [TBL] [Abstract][Full Text] [Related]
16. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247 [TBL] [Abstract][Full Text] [Related]
17. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men. Adler SP; Manganello AM; Lee R; McVoy MA; Nixon DE; Plotkin S; Mocarski E; Cox JH; Fast PE; Nesterenko PA; Murray SE; Hill AB; Kemble G J Infect Dis; 2016 Nov; 214(9):1341-1348. PubMed ID: 27521362 [TBL] [Abstract][Full Text] [Related]
18. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. Gönczöl E; Ianacone J; Furlini G; Ho W; Plotkin SA J Infect Dis; 1989 May; 159(5):851-9. PubMed ID: 2540246 [TBL] [Abstract][Full Text] [Related]
19. Progress toward developing a cytomegalovirus vaccine. Marshall GS; Plotkin SA Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034 [TBL] [Abstract][Full Text] [Related]
20. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. Gerna G; Lilleri D New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]